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In the  era  of Directly  Acting  anti  HCV  Antivirals  treatment  of  hepatitis  C is  successful  in the  majority
of  persons  treated.  However,  treatment  of persons  with  HIV  or who  inject  drugs  remains  challenging
because  of special  issues:  drug–drug  interactions  with  antiretroviral,  psychiatric  and  drug  substitution
therapies,  treatment  adherence,  impact  of treatment  on  HIV  disease  course  or  on  risk  of bacterial  infec-
tions.  Sofosbuvir  induced  sustained  virologic  response  in  91%  of  23  HIV/HCV  coinfected  persons  treated  in
combination  with  ribavirin  and  pegylated  interferon,  in 83% of 497  treated  in  combination  with  ribavirin
and  in all  50  patients  infected  with  HCV  GT1  treated  in combination  with  ledipasvir  and  ribavirin.  Thenjection drugs users
ofosbuvir
rates  of  efﬁcacy  in  HCV–HIV  coinfected  were  almost  the  same  as  those  observed  in  HCV  monoinfected
suggesting  that the  efﬁcacy  of  sofosbuvir  is not  reduced  by HIV  coinfection.  There  are no  data  on  the
efﬁcacy  of  sofosbuvir  in injection  drugs  users.  The  pangenotypic  activity,  the  high  barrier  to  resistance,
the  modest  potential  for  drug–drug  interactions  makes  sofosbuvir  a reference  drug  for  the treatment  of
these  two  special  populations.
©  2014  Editrice  Gastroenterologica  Italiana  S.r.l. Published  by  Elsevier  Ltd.  
D lice. Introduction
According to recent estimates, more than 185 million people
round the world are infected with the hepatitis C virus (HCV),
50 000 of whom die each year [1]. HCV is transmitted primarily
s a result of direct, through-the-skin exposure to infected blood
1]. Certain groups are at higher risk of HCV infection, and People
ho Inject Drugs (PWID) are an important risk category. In middle-
nd high-income countries, most HCV infections occur among peo-
le who use unsterile equipment to inject drugs and contaminated
rug solutions [1,2]. Of the estimated 16 million people in 148
ountries who actively inject drugs, 10 million are infected with
CV [2].
Human immunodeﬁciency virus (HIV) and HCV have common
outes of transmission, and it is estimated that, globally, 4–5 mil-
ion persons out of the 185 million infected by HCV are also
oinfected by HIV [3]. Sexual transmission of HCV is also com-
Open access under CC BY-NC-Non in Persons Living with HIV (PLHIV), particularly in men  who
ave sex with men  (MSM)  [4]. In several recent outbreaks of
CV infection among HIV infected MSM  in Europe, Australia and
∗ Corresponding author at: Division of Infectious Diseases, Ospedale Niguarda Ca’
randa, Piazza Ospedale Maggiore 3, 20162 Milano, Italy. Tel.: +39 0264442189;
ax:  +39 02 64442681.
E-mail  address: massimo.puoti@ospedaleniguarda.it (M.  Puoti).
ttp://dx.doi.org/10.1016/j.dld.2014.09.027
590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Othe US, transmission has been linked to sexual exposure as well
as, potentially, to underreported use of non-injecting recreational
drugs [4].
These two  groups have a high rate of acquisition of HCV: in
the ﬁrst year of injection drug use more than 50% of the subjects
acquire HCV and the rate of HCV infection in PLHIV is 1000 higher
than that of the general population [2]. So they are an impor-
tant epidemiological reservoir for the persistence of the virus in
the general population. Thus elimination of HCV infection in these
subjects may  not only improve individual health status but also
may also decrease circulation of HCV infection [2]. In the era of
Directly Acting anti HCV Antivirals (DAAs) treatment of Hepatitis C
has become successful in the majority of persons treated [5]. How-
ever, treatment of PLHIV and PWID remains challenging because
of special issues: drug–drug interactions with antiretroviral, psy-
chiatric and opiate substitution therapies, treatment adherence,
impact of treatment on HIV disease course or on risk of bacterial
infections [2,5].
Sofosbuvir (SOF) is a pyrimidine nucleotide analogue that
inhibits HCV NS5B RNA dependent RNA polymerase that is
essential for viral replication and is relatively conserved across
HCV genotypes and HCV quasispecies [5–7]. Thus sofosbuvir has
nse.pangenotypic activity and a high barrier to resistance [7]. Sofos-
buvir in combination with ribavirin with or without pegylated
interferon, and in combination with other anti HCV DAAs achieves
high response rates in the treatment of hepatitis C [7].
pen access under CC BY-NC-ND license.
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This article reviews the rationale for treatment of hepatitis C and
he efﬁcacy and tolerability of sofosbuvir in these two  groups.
.  Rationale for treatment of hepatitis C in PLHIV
Since the introduction of combination antiretroviral therapy
cART), liver disease has become a major cause of morbidity and
ortality in HIV-infected persons and is currently one of the most
requent causes of non-HIV-related death among HIV-infected per-
ons [3]. Whether HCV has a negative impact on the progression
f HIV infection has been extensively debated. However, there is
ncreasing evidence that HCV coinfection has a harmful effect on the
rogression of HIV infection, impairing virological and immunolog-
cal response to cART, and on comorbid conditions such as renal,
one and cardiovascular diseases, and may  increase the risk of
ortality despite the use of cART [8].
Sustained viral response (SVR) (equivalent to eradication of
CV) after administering anti-HCV therapy is associated with
mproved survival and reduced liver decompensation in patients
ith chronic hepatitis C with or without HIV infection. In HIV/HCV
oinfection, SVR may  also decrease the progression of HIV infection
nd mortality not related to liver disease [9].
One of the major issues in the treatment of Hepatitis C in
LHIV are the potential interactions between anti HCV and anti HIV
ntivirals. Sofosbuvir is a substrate for P glycoprotein (P-gp) and
reast Cancer Resistant Protein [7]. Thus it is expected that sofos-
uvir concentrations may  be reduced by co-administration with
otent P-gp inducers. Sofosbuvir is prodrug that undergoes exten-
ive intracellular hepatic metabolism to a pharmacologically active
ridine triphosphate form (GS-461203). Dephosphorylation results
n the formation of GS-331007 that is the predominant circulat-
ng metabolite without anti HCV activity in vitro. Renal clearance
s the major elimination pathway for GS-331007 thus no inter-
ctions are expected at the level of hepatic cytochromes [7]. For
hese reasons Tipranavir is the only antiretroviral that may  signiﬁ-
antly modify sofosbuvir concentrations [7]. In healthy volunteers
o clinically signiﬁcant drug interactions were found between SOF
nd efavirenz, emtricitabine, raltegravir, darunavir/ritonavir and
enofovir [10]. Thus SOF apparently has no potentially signiﬁcant
rug–drug interactions with most of the antiretrovirals.
. Sofosbuvir in combination with pegylated interferon
nd  ribavirin in PLHIV
A  single-centre, open-label, single-arm trial assessed the efﬁ-
acy and safety of a 12 week course of sofosbuvir 400 mg  daily in
ombination with pegylated interferon alfa 2a 180 mcg  per week
nd weight-based ribavirin 1000–1200 mg  [11]. The study included
3 subjects on stable antiretroviral therapy for more than 8 weeks,
ith CD4 counts > 200/mmc and without cirrhosis. Fifteen subjects
ere infected with HCV genotype 1a, 4 with HCV genotype 1b,
 with HCV genotype 2, 2 with HCV genotype 3 and 1 with HCV
enotype 4. Most of the patients (18/23) were male, 8 were black
nd only 5 had the favourable IL28b genotype CC. Mean CD4 cell
ount was 562 cells/mmc and all patients were on treatment with
enofovir and emtricitabine in combination with: efavirenz in 7,
tazanavir/ritonavir in 5, raltegravir in 6, darunavir/ritonavir in 4
nd rilpivirine in 1. Twenty two had HCVRNA <25 IU/mL after 2
eeks of therapy and all 23 from the 4th week of therapy. One
atient with HCV genotype 1a withdrew consent and discontin-
ed treatment after 6 weeks. Two patients discontinued at week and 8 due to adverse events. All patients maintained HCVRNA
25 IU/mL until the end of treatment. Two patients with HCV Geno-
ype 1a relapsed after discontinuing treatment one of them being
he patient that withdrew consent after 6 weeks of treatment.isease 46 (2014) S206–S211 S207
Thus  21/23 showed SVR 12 weeks after discontinuing treatment.
No patient had serious adverse events, two patients discontinued
at week 6 and 8 respectively due to anaemia and altered mood.
Seven patients showed grade 3 adverse events and 4 patients
showed grade 4 laboratory abnormalities: two  neutropenia and
two indirect hyperbilirubinemia presumably related to concurrent
atazanavir use. Percentage of CD4 counts remained stable during
and after treatment, no HIV virologic breakthrough was observed
during treatment, or in the 4 weeks after discontinuing treatment,
and no change in antiretroviral regimen was  made throughout the
study [11]. Thus a 12-week treatment regimen of SOF in combi-
nation with peginterferon and ribavirin was shown to be highly
effective in this pilot study of HCV/HIV-coinfected patients. SVR12
rates were similar to those seen with this regimen in HCV mono-
infected patients [7] and SOF was  well tolerated in patients using
a wide variety of HIV antiretroviral regimens. A low risk of HIV
virologic breakthrough was observed with this treatment [11].
4.  Sofosbuvir and ribavirin in PLHIV
In HCV mono-infected patients several studies have demon-
strated the possibility of obtaining high rates of SVR with interferon
free combinations of DAAs [5]. Peginterferon has many side effects
and contraindications and many PLHIV are unwilling to take inter-
feron [12]. For these reasons only a minority of PLHIV in care
have been treated with peginterferon based therapies [13]. Thus
the availability of an effective HCV interferon free regimen will be
a turning point in the management of hepatitis C in PLHIV. In a
recently published study Sulkowsky and co-workers reported the
results of an open-label, non-randomized, uncontrolled phase 3
trial conducted at 34 treatment centres in the United States and
Puerto Rico between August 2012 and November 2013 evaluat-
ing treatment with SOF and RBV 1000–1200 mg  in patients with
HCV genotypes 1, 2, or 3 and concurrent HIV [14]. Patients were
required to be receiving ART with HIV RNA values of 50 copies/mL
or less and a CD4 T-cell count of more than 200 cells/L or to have
untreated HIV infection with a CD4 T-cell count of more than 500
cells/L. Overall, 330 patients coinfected with HIV and HCV were
screened for the study, 224 were enrolled and 223 began treatment.
Of the treatment-naïve patients, 114 had HCV genotype 1 and 68
had HCV genotype 2 or 3, while 41 treatment-experienced par-
ticipants who had been treated with peginterferon-ribavirin had
HCV genotype 2 or 3, for a total of 223 participants. Treatment-
naïve patients with HCV genotype 2 or 3 received 400 mg of SOF
and 1000–1200 weight-based RBV for 12 weeks and treatment-
naïve patients with HCV genotype 1 and treatment-experienced
patients with HCV genotype 2 or 3 received the same treatment for
24 weeks. Of the patients185 were male, 52 were African American,
49 were interferon ineligible, and 22 had cirrhosis – 12 determined
by liver biopsy and 10 by FIBROSURE. Cirrhosis was more com-
mon in treatment-experienced patients and the median CD4 cell
count was 562–581 cells/L. Among treatment-naïve patients with
genotype 1, the majority had subtype 1a and 32% were black.
In  each treatment group, 90% to 98% of patients were on ART.
All 223 patients were taking tenofovir and emtricitabine, 78 were
taking efavirenz, 39 atazanavir ritonavir, 34 darunavir/ritonavir, 36
raltegravir, 14 rilpivirine and 11 other combinations. Of 11 patients
not on ART, 5 had an HIV RNA level lower than 50 copies/mL at
baseline.
Among treatment-naïve participants, 87 patients (76%) of 114
(95% CI, 67–84%) with genotype 1, 23 patients (88%) of 26 with
genotype 2 (95% CI, 70–985), and 28 patients (67%) of 42 with
genotype 3 (95% CI, 51–80%) achieved SVR12. Among treatment-
experienced participants, 22 patients (92%) of 24 with genotype
2 (95% CI, 73–99%) and 16 patients (94%) of 17 (95% CI, 71–100%)
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chieved SVR12. Seventeen out of 22 cirrhotic patients showed SVR
2 (3/5 HCV GT1 5/5 HCV GT2 and 9/12 HCV GT3). Notably, SVR12
ates were 82% (95% CI, 73–89%) among the 103 patients with
CV genotype 1 who completed study treatment and 27% (95% CI,
–61%) among the 11 patients who discontinued treatment early.
mong patients with HCV genotype 1, exploratory multivariable
nalysis indicated that non-black race (OR, 2.87; 95% CI, 1.01–8.20;
 = 0.049), HCV genotype 1a (OR, 3.42; 95% CI, 1.15–10.16; P = 0.03),
nd completion of 24 weeks of study treatment (OR, 17.54; 95% CI,
.77–83.33; P < 0.001) were associated with achieving SVR12.
The reasons for non response in 50 HCV GT2 were relapse in one
xperienced patient, non adherence in one patient, withdrawal of
onsent in two and loss to follow up in two patients. The reasons
or non-response in HCV GT3 were relapse in 12/50 naïves treated
or 12 weeks and in 1/17 experienced treated for 24 weeks. One
aïve patient was lost to follow up and one died after treatment
ompletion of causes unrelated to treatment.
The most common adverse events were fatigue, insomnia,
eadache, and nausea. Seven patients (3%) discontinued HCV
reatment due to adverse events without any relationship with
reatment duration. Indirect hyperbilirubinemia was  common
mong patients taking atazanavir/ritonavir. No adverse effect on
IV disease or its treatment was observed.
The preliminary results of a second study “PHOTON II” were
resented recently at the 20th International AIDS Conference [15].
In this study, carried out in Europe and Australia, 274 individuals
nfected with HIV and HCV GT1-4, including 20% with compensated
irrhosis, were enrolled to receive SOF 400 mg  QD and weight-
ased RBV 1000–1200 mg/day. GT 1, 3, 4 treatment naïve and GT
, 3 treatment-experienced patients received 24 weeks of therapy
nd GT 2 treatment naïve 12 weeks. Most of the patients (81%) were
ale, 97% were receiving ART and median CD4 was > 500 cell/L
n all groups. All 265 patients on ART were taking tenofovir and
mtricitabine, 25% were taking efavirenz, 17% atazanavir/ritonavir,
1% darunavir/ritonavir, 23% raltegravir, 5% rilpivirine, 10% were on
ther treatments. Two hundred thirty seven (86%) out of 274 (95% CI
2–90%) achieved SVR 12. Among treatment-naïve participants 95
atients (85%) of 112 (95% CI, 78–92%) with genotype 1, 17 patients
89%) of 19 with genotype 2 (95% CI, 75–100%), 52 patients (91%)
f 57 with genotype 3 (95% CI, 84–98%) and 26 (84%) out of 31 with
enotype 4 (95% CI 77–91%) achieved SVR12. Among treatment-
xperienced participants, 5 patients (83%) of 6 with genotype 2 and
2 patients (86%) of 49 with genotype 3 (95% CI, 76–96%) achieved
VR12. Among cirrhotic patients SVR 12 was observed in 44 (81%;
5% CI 71–91%) out of 54 (11/17 HCV GT1, 1/1 naïves 2/2 experi-
nced with HCV GT2, 3/3 naïves and 18/23 experienced with HCV
T3 and 7/8 HCV GT4). Thirty one patients relapsed, 1 had break-
hrough and 6 were lost to follow up or withdrew consent. HCV
esistance testing with deep sequencing was performed in 29 out
f 32 with treatment failure; no S282T mutation was detected while
ve patients showed L159F mutation. Treatment discontinuations
rom SOF due to adverse events (AEs) were observed in 5/274 (2%)
f patients and grade 3/4 AEs were reported in 15/274 (6%). No
hange in CD4% was observed through SVR12. Four patients had an
IV-RNA rebound that did not require ARV modiﬁcation.
It  is possible to cumulatively analyze the two  studies in which
97 PLHIV were enrolled, the highest number of PLHIV treated with
FN free therapy for HCV infection.
SVR 12 was obtained in 412 (83%; 95% CI 82–84%): 181 (80%; 95%
I 78–82%) out of 226 infected by HCV GT1, 67 (89%; 95% CI 87–91%)
ut of 75 infected by HCV GT2, 138 (84%; 95% CI 81–86%) out of
65 infected by HCV GT3 and 26 (84%; 95% CI 79–89%) out of 31
nfected by HCV GT4. Fig. 1 illustrates the cumulative rates of SVR12
bserved in the two studies, obtained by stratifying patients treated
n the two studies according to HCV genotype, previous treatment
ith peginterferon and ribavirin and treatment duration. SVR12isease 46 (2014) S206–S211
was  less than 80% only in HCV GT1 naïve cirrhotics treated for 24
weeks, in HCV GT3 naïves treated for 12 weeks and in HCV GT3
experienced cirrhotics even if treated for 24 weeks. Therefore, pro-
longation of treatment to 24 weeks seems to be required in naïve
patients infected by HCV GT3 and “something” should be added to
optimize the efﬁcacy of SOF + RBV treatment administered for 24
weeks in patients infected by HCV GT1, especially if cirrhotics, and
in experienced cirrhotics with HCV GT3 infection.
In conclusion the two studies demonstrated a good tolerability,
and estimates of efﬁcacy greater than 80% in a large and heteroge-
neous population of more than 450 patients treated with sofosbuvir
and ribavirin.
Hepatitis C is a heterogeneous disease so HCV genotype, expo-
sure to previous treatment with peginterferon and ribavirin and
the presence of cirrhosis are strongly related to response to antivi-
ral treatment also in PLHIV. The heterogeneity of this large study
population permits a series of indications for clinical practice to
be derived from these two  studies. The robust demonstration of an
efﬁcacy greater than 85% in most of the subgroups of PLHIV enrolled
in these two studies, the inclusion of a large number of patients
intolerant to peginterferon and the possibility of maintaining most
of the concurrent cART regimen due to lack of interactions with
almost all antiretrovirals suggest that treatment with SOF + RBV
could be a ﬁrst line choice for the treatment of Hepatitis C in the
following subgroup of PLHIV:
– naïve infected by HCV GT2 with a treatment duration of 12 weeks.
– naïve infected by HCV GT3 and experienced with HCV GT2  with
or  without cirrhosis and experienced HCV GT3 without cirrhosis
with  a treatment duration of 24 weeks.
–  In patients with HCV GT1 especially without cirrhosis, the rates of
SVR are similar to those obtained with INF based triple therapies,
however,  higher rates of SVR have been obtained by combining
sofosbuvir with other DAAs in HIV uninfected patients.
The number of HCV GT4 naïve patients is not sufﬁcient to draw a
ﬁrm conclusion, however, the lower limit of the conﬁdence interval
of the estimate of SVR12 in 31 patients was  79%.
Although there are no studies comparing the efﬁcacy of SOF and
RBV in persons with and without HIV coinfection and there is no
meta-analysis based on individual patients’ data, it could be possi-
ble to compare the efﬁcacy of SOF and RBV observed in patients with
and without HIV coinfection by analysing the data from different
studies. Fig. 2 shows the comparison between the data from HIV
uninfected subjects obtained in registration studies and reported
in the SOF summary of product characteristics [16] with those
observed in PLHIV in the PHOTON I and PHOTON II studies.
The  rates of efﬁcacy in PLHIV are almost the same across all
subgroups and thus these data suggest that the efﬁcacy of SOF and
RBV is not reduced by HIV coinfection. Thus, in the sofosbuvir era,
PLHIV are no longer a special population with an unmet need.
5.  Sofosbuvir in combination with other DAAs in PLHIV
The  use of sofosbuvir in combination with a second DAA has
been extremely successful in HCV mono-infected persons with HCV
genotype 1. Two small pilot studies [17,18] showed SVR12 rates
higher than 95% when sofosbuvir was  combined with daclatasvir
(a NS5A inhibitor) and with simeprevir (a second wave pro-
tease inhibitor) in small study population. The combination with
simeprevir was able to induce the same SVR rates also in patients
with cirrhosis.
An  efﬁcacy higher than 95% was  also obtained in large phase III
studies assessing the efﬁcacy of sofosbuvir co-formulated with ledi-
pasvir (a NS5A inhibitor) in a ﬁxed drug combination in a large study
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Fig. 1. Cumulative estimates with 95% conﬁdence intervals of the percentage of Sustained Virologic Response 12 weeks after discontinuing sofosbuvir and ribavirin (SVR12)
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xperienced (exp) presence of cirrhosis, and duration of treatment.
opulation of 1952 subjects. The study population included naïve
atients, treatment-experienced patients who had failed pegin-
erferon and ribavirin with or without telaprevir or boceprevir,
atients with well compensated and advanced cirrhosis [19–21].
he efﬁcacy of the ﬁxed dose combination of Ledipasvir and
ig. 2. Estimates of the percentage of Sustained Virologic Response 12 weeks after discon
67  HCV monoinfected patients stratiﬁed according to the presence of cirrhosis (cirr.) and
exp). (HCV G) previous treatment with pegylated interferon and ribavirin, naïves and
sofosbuvir  was independent from the coadministration of ribavirin,
and in non cirrhotic patients, from treatment duration of 8 vs.
12 weeks.
Although US and European recommendations [22,23] sug-
gest the extension of the use of sofosbuvir combinations with
tinuing sofosbuvir and ribavirin (SVR12) in 497 HIV/HCV coinfected patients and in
 previous treatment with pegylated interferon and ribavirin naïves and experienced
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aclatasvir or simeprevir in PLHIV, there are no data on the efﬁ-
acy and tolerability of these combinations in this group of patients.
imeprevir has a moderate potential for drug–drug interactions
ith anti-HIV protease inhibitors, efavirenz and nevirapine [24]
nd the daclatasvir dosage should be adjusted when used with
favirenz or ritonavir boosted anti HIV protease inhibitors [24].
hus, the concurrent cART should be adjusted in a relevant pro-
ortion of patients who are candidates for simeprevir or daclatasvir
dministration. Preliminary results have recently been reported for
RADICATE”, an NIH funded study on the efﬁcacy of ledipasvir and
ofosbuvir ﬁxed dose combination administered for 12 weeks with-
ut ribavirin in PLHIV [25]. Fifty HIV/HCV coinfected patients with
CV GT1, without cirrhosis were enrolled: 13 patients were not
n concurrent cART but had stable CD4 and HIV RNA < 500 cp/mL
r had CD4 > 500/mmc and 37 had been on a stable cART for at
east 8 weeks with tenofovir/emtricitabine plus rilpivirine (11/37)
nd/or, raltegravir (13/37) and/or efavirenz (16/37). Forty-two
ere African American, 42 infected with HCV GT1a and 13 had
iver ﬁbrosis METAVIR F3 stage. Only 34 patients reached the 16th
eek of the study and all 34 showed SVR4. SVR12 was  observed
n all 10 patients not under cART who reached the 24th week of
he study. The ﬁtted HCV viral kinetic model showed a similar
ecline in both the group undergoing cART and the group with-
ut cART. Only one patient who skipped cART for 4 days showed
n HIV breakthrough but HIV replication was re-suppressed with
he same regimen. The tolerability was very good, only one patient
howed a grade 3 event (pneumonia) and three patients grade ≥3
ab abnormalities (1 elevated AST, 1 neutropenia and 1 grade 4
PK elevation).
If  conﬁrmed by further data analysis these preliminary results
uggest that an interferon and ribavirin free ﬁxed dose combina-
ion of sofosbuvir and Ledipasvir is equally effective in PLHIV as in
CV mono-infected and that it could become the ﬁrst line option
n PLHIV with HCV Genotype 1 coinfection.
. Treatment of hepatitis C in PWID
PWID are often infected at a young age, which could imply a
low development of cirrhosis. On the other hand, more than 75%
f PWID are males and unhealthy behaviour, including high alcohol
onsumption, may  be frequent [26]. Thus progression to cirrhosis in
he long term may  occur in a signiﬁcant proportion of PWID. A study
n liver histology at autopsy of 102 PWID in Norway showed that
bout 1/3 of Injection Drugs Users (IDU) chronically infected with
CV progressed to advanced liver ﬁbrosis within three decades
fter exposure [27]. However, the all-cause mortality in PWID is
igh and in the ﬁrst three decades after HCV infection competi-
ive causes of mortality may  reduce survival of PWID. Recently, a
ohort study on 523 drug users followed for 33 years in Norway
howed no difference between HCV RNA positive and HCV RNA
egative individuals in the ﬁrst three decades after HCV infection.
owever, among PWID with chronic HCV infection who  survived
ill the age of 50, HCV infection emerged as the main cause of death.
28] Thus, from the point of view of individual health, HCV infection
ay reduce life expectancy only if the individual survives for more
han 20 years after infection and injection drug use initiation.
Injection drug use is the primary mode of transmission of HCV
n developed countries [29], with 15–90% of injecting drug users
esting positive for HCV antibodies [30]. Current interventions for
educing HCV transmission focus on reducing the frequency of
njecting and syringe sharing/unsafe injection [29]. These may  have
educed HCV transmission in some settings [31], but there is no
vidence for substantial reductions in HCV prevalence.
A  simpliﬁed HCV transmission model provided evidence that
ntiviral treatment at achievable rates may  be an effective primaryisease 46 (2014) S206–S211
prevention  tool for substantially reducing the prevalence of HCV
infection, despite the persistent risk of re-infection. Higher SVR
with improved and accessible treatment regimens increases the
impact of treatment [32].
To  date, uptake of therapy remains low among PWID, and
is rarely encouraged [33]. Many factors contribute to the low
treatment rates in IDU including concerns about re-infection, the
low priority of injectors for scarce treatment resources and the
lack of evidence showing unequivocal beneﬁts [2]. Nonetheless,
the available evidence suggests that IDU can be treated success-
fully with peginterferon and ribavirin, especially when innovative
approaches to delivering therapy are used [2]. However, with
peginterferon based therapies low treatment willingness, and high
psychiatric comorbidity may  contribute to low treatment rates [2].
A study showed that treating chronic HCV infection in injectors
and ex- or non-injectors is cost-effective, but treating injectors may
be more cost-effective when the chronic HCV prevalence among
IDU is below 60% [34]. However, the results of these models should
be conﬁrmed by empirical studies examining the treatment of
IDUs and measuring the effects on prevalence. Nevertheless, anti-
HCV treatment is supported by international recommendations
which suggest that treatment among PWID is feasible and provide
a framework for HCV assessment, management, and treatment
[2]. Further research is needed to evaluate strategies to enhance
assessment, adherence, and SVR among PWID, particularly as new
treatments for HCV infection become available.
In PWID the distribution of HCV genotypes is more heteroge-
neous than in the general population [30] so different schedules
of antiviral treatment are needed. In addition, many PWID are on
opiate substitution therapy, assume other drugs for psychiatric
comorbidities or illicit drugs [2]. So drug–drug interactions may
be a concern when treating HCV with drugs which can poten-
tially interfere with the metabolism of opiates, psychiatric and illicit
drugs [2].
Sofosbuvir with its pangenotypic activity, its low potential for
drug–drug interaction and its possibility for use without interferon
could be the reference antiviral for the treatment of PWID. No
patient actively injecting drugs was enrolled in registration stud-
ies with sofosbuvir, therefore, studies on this population are still
warranted. However, sofosbuvir efﬁcacy and tolerability have been
demonstrated in 53 patients with contraindications to interferon
due to psychiatric comorbidities [16].
7. Conclusions
The pangenotypic activity, the high barrier to resistance, the
modest potential for drug–drug interactions make sofosbuvir a ref-
erence drug for the treatment of PLHIV and PWID. Data on the
efﬁcacy and tolerability of sofosbuvir in PLHIV are robust because
497 PLHIV were enrolled in the registration studies PHOTON I and
PHOTON II. The efﬁcacy and tolerability of sofosbuvir in PLHIV are
equal or better to those observed in HCV mono-infected. Sofosbuvir
in combination with ribavirin is the standard reference combina-
tion for the treatment of Hepatitis C genotype 2 and 3 in PLHIV,
and probably the sofosbuvir and ledipasvir ﬁxed dose combination
will become the ﬁrst line option in patients infected by HCV GT1.
Other potential uses of sofosbuvir in combination with Simeprevir
or Daclatasvir are promising but the data on use of these combos
in PLHIV are still lacking. Sofosbuvir also has a great potential for
use in PWID, however, data in this population are still needed.
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